Oseltamivir Dosing for Influenza
Treatment Dosing
For otherwise healthy adults and adolescents ≥13 years, prescribe oseltamivir 75 mg orally twice daily for 5 days, initiated within 48 hours of symptom onset. 1, 2
Adults and Adolescents (≥13 years)
- Standard dose: 75 mg orally twice daily for 5 days 1, 2
- Timing: Initiate within 48 hours of symptom onset for maximum benefit; earlier initiation (within 12–24 hours) yields an additional 1–3 days of symptom reduction compared to starting at 48 hours 1, 3, 4
- Administration: May be taken with or without food, though taking with meals significantly reduces nausea and vomiting (the most common adverse effects, occurring in ~10% of patients) 1, 2, 3
Pediatric Patients (≥12 months) – Weight-Based Dosing
Use the oral suspension formulation (6 mg/mL) for accurate dosing in children: 1, 2
| Body Weight | Dose per Administration | Volume (6 mg/mL suspension) | Frequency | Duration |
|---|---|---|---|---|
| ≤15 kg | 30 mg | 5 mL | Twice daily | 5 days |
| >15–23 kg | 45 mg | 7.5 mL | Twice daily | 5 days |
| >23–40 kg | 60 mg | 10 mL | Twice daily | 5 days |
| >40 kg | 75 mg | 12.5 mL | Twice daily | 5 days |
Infants (<12 months) – Age-Based Dosing
- Term infants 9–11 months: 3.5 mg/kg per dose twice daily for 5 days 1, 5
- Term infants 0–8 months: 3.0 mg/kg per dose twice daily for 5 days 1, 5, 2
- Critical measurement requirement: Use a calibrated 3–5 mL oral syringe; household spoons or the manufacturer-supplied syringe are inadequate for these small volumes 1
Preterm Infants – Post-Menstrual Age-Based Dosing
Preterm infants require substantially lower doses due to immature renal function; using term-infant dosing will cause toxic drug accumulation: 1, 5
| Post-Menstrual Age | Dose (mg/kg) | Frequency | Duration |
|---|---|---|---|
| <38 weeks | 1.0 mg/kg | Twice daily | 5 days |
| 38–40 weeks | 1.5 mg/kg | Twice daily | 5 days |
| >40 weeks | 3.0 mg/kg | Twice daily | 5 days |
- Post-menstrual age calculation: Gestational age + chronologic age 1
- Specialist consultation: For extremely preterm infants (<28 weeks PMA), consult pediatric infectious disease before initiating therapy 1
Prophylaxis Dosing
For post-exposure prophylaxis in adults and adolescents ≥13 years, prescribe oseltamivir 75 mg orally once daily for 10 days, initiated within 48 hours of exposure to a confirmed influenza case. 5, 6, 2
Adults and Adolescents (≥13 years)
- Post-exposure prophylaxis: 75 mg once daily for 10 days 5, 6, 2
- Seasonal prophylaxis: 75 mg once daily for up to 6 weeks during community outbreaks 6, 2
- Timing: Initiate within 48 hours of close contact with an infected individual 5, 6
Pediatric Patients (≥12 months) – Weight-Based Prophylaxis
Use the same weight-based doses as treatment, but administered once daily instead of twice daily for 10 days: 5, 6
| Body Weight | Dose | Volume (6 mg/mL suspension) | Frequency | Duration |
|---|---|---|---|---|
| ≤15 kg | 30 mg | 5 mL | Once daily | 10 days |
| >15–23 kg | 45 mg | 7.5 mL | Once daily | 10 days |
| >23–40 kg | 60 mg | 10 mL | Once daily | 10 days |
| >40 kg | 75 mg | 12.5 mL | Once daily | 10 days |
Infants (3–11 months)
- Dose: 3.0 mg/kg once daily for 10 days 5, 6
- Infants <3 months: Prophylaxis is not recommended unless the clinical situation is judged critical, due to limited safety data 1, 5, 6
Renal Impairment Adjustments
Dose adjustment is mandatory for patients with creatinine clearance <60 mL/min to prevent drug accumulation and toxicity: 1, 5
Treatment Dosing in Renal Impairment
- CrCl 10–30 mL/min: 75 mg once daily (instead of twice daily) for 5 days 1, 5, 2
- Alternative low-dose option: 30 mg once daily for 5 days 1
Prophylaxis Dosing in Renal Impairment
- CrCl 10–30 mL/min: Either 30 mg once daily for 10 days OR 75 mg every other day for 10 days (total of 5 doses) 1, 5, 6
End-Stage Renal Disease
- Not recommended for patients with ESRD not undergoing dialysis 2
Alternative Antiviral: Zanamivir
If oseltamivir cannot be administered orally, if there is documented oseltamivir resistance, or if the patient has a true oseltamivir allergy, zanamivir is the preferred alternative neuraminidase inhibitor: 6, 7
Zanamivir Dosing
- Treatment: 10 mg (two 5-mg inhalations) twice daily for 5 days 6
- Prophylaxis: 10 mg (two 5-mg inhalations) once daily for 10 days 6
- Age restriction: Approved for patients ≥5 years old 6
Critical Contraindication
- Zanamivir is contraindicated in patients with underlying airway disease (asthma, COPD) due to risk of bronchospasm 6
- This makes zanamivir unsuitable for many high-risk patients who would most benefit from antiviral therapy 6
Special Populations
Pregnancy and Postpartum
- Pregnant women receive the standard adult dose: 75 mg twice daily for 5 days (treatment) or 75 mg once daily for 10 days (prophylaxis) 5
- Oseltamivir is preferred over zanamivir in pregnancy due to zanamivir's inhaled route and potential respiratory complications 5
- Breastfeeding is not a contraindication to oseltamivir use 5
High-Risk Patients Requiring Treatment Regardless of Timing
The following groups should receive treatment even if presenting >48 hours after symptom onset: 5
- All hospitalized patients with presumed influenza 5
- Children <2 years of age 5
- Adults ≥65 years of age 5
- Pregnant women and women up to 2 weeks postpartum 5
- Immunocompromised patients (may require treatment >5 days) 5
- Patients with chronic cardiac, pulmonary, renal, hepatic, neurologic, hematologic, or metabolic disorders 5
- Residents of long-term care facilities 5
Formulation and Administration
Available Formulations
Compounding Option
- If commercial suspension is unavailable, capsules may be opened and mixed with simple syrup or Ora-Sweet SF to achieve 6 mg/mL concentration 1
- Pharmacies can compound suspension according to package insert instructions 1, 2
Administration Tips
- With food: Significantly reduces nausea and vomiting without affecting antiviral efficacy 1, 3, 4
- Complete the full 5-day course even if symptoms resolve earlier, to ensure adequate viral suppression and prevent resistance 1
Common Pitfalls to Avoid
- Do not confuse prophylaxis dosing (once daily) with treatment dosing (twice daily) – this is a frequent prescribing error 6
- Do not use weight-based categorical dosing (≤15 kg = 30 mg) for infants <12 months – use mg/kg dosing instead 1
- Do not apply term-infant dosing to preterm infants – post-menstrual age-based dosing is required to avoid toxicity 1, 5
- Do not round doses inappropriately in infants – calculate the exact mg/kg dose and measure precisely 1
- Do not fail to adjust dosing in renal impairment (CrCl <60 mL/min) – this leads to drug accumulation 1, 5
- Do not withhold treatment from high-risk patients presenting >48 hours after symptom onset – they still benefit significantly 5, 8
- Do not use oseltamivir within 2 weeks after live attenuated influenza vaccine (LAIV) – it may interfere with vaccine efficacy 1